Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Background: Direct real-world comparisons of satralizumab and rituximab in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder remain uncommon. Methods: We conducted a multicenter retrospective cohort study across eight hospitals in Fujian Province, China. Patients aged 12 years or older contributed treatment episodes beginning at the first verifiable administration of satralizumab or rituximab.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
